{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T05:16:32Z","timestamp":1740287792870,"version":"3.37.3"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,7,17]],"date-time":"2010-07-17T00:00:00Z","timestamp":1279324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11899-010-0058-6","type":"journal-article","created":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T09:53:19Z","timestamp":1279273999000},"page":"177-184","source":"Crossref","is-referenced-by-count":4,"title":["Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1007","volume":"5","author":[{"given":"Lia","family":"Gore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Trippett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,17]]},"reference":[{"key":"58_CR1","unstructured":"Ries LAG, Smith MA, Gurney JG, et al. (eds): Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999."},{"key":"58_CR2","unstructured":"Magrath IT: Malignant non-Hodgkin\u2019s lymphomas in children. In Principles and Practice of Pediatric Oncology. Edited by Pizzo PA, Poplack DG. Philadelphia: Lippincott Williams & Wilkins; 2002:661\u2013705."},{"key":"58_CR3","first-page":"205","volume":"284","author":"RJ Biggar","year":"2000","unstructured":"Biggar RJ, Frisch M, Goedert JJ: Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. JAMA 2000, 284:205\u2013209.","journal-title":"AIDS-Cancer Match Registry Study Group. JAMA"},{"key":"58_CR4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1998.16.5.1729","volume":"16","author":"MO Granovsky","year":"1998","unstructured":"Granovsky MO, Mueller BU, Nicholson HS, et al.: Cancer in human immunodeficiency virus-infected children: a case series from the Children\u2019s Cancer Group and the National Cancer Institute. J Clin Oncol 1998, 16:1729\u20131735.","journal-title":"J Clin Oncol"},{"key":"58_CR5","doi-asserted-by":"crossref","unstructured":"Gaidano G, Carbone A, Dalla-Favera R: Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Natl Cancer Inst Monogr 1998:95\u2013100.","DOI":"10.1093\/oxfordjournals.jncimonographs.a024181"},{"key":"58_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V87.2.423.bloodjournal872423","volume":"15","author":"AM Taylor","year":"1996","unstructured":"Taylor AM, Metcalfe JA, Thick J, Mak YF: Leukemia and lymphoma in ataxia telangiectasia. Blood 1996, 15:423\u2013438.","journal-title":"Blood"},{"key":"58_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.leu.2403221","volume":"18","author":"F Gumy-Pause","year":"2004","unstructured":"Gumy-Pause F, Wacker P, Sappino AP: ATM gene and lymphoid malignancies. Leukemia 2004, 18:238\u2013242.","journal-title":"Leukemia"},{"key":"58_CR8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","volume":"125","author":"KE Sullivan","year":"1994","unstructured":"Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA: A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994, 125:876\u2013885.","journal-title":"J Pediatr"},{"key":"58_CR9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM199605093341906","volume":"334","author":"JT Sandlund","year":"1996","unstructured":"Sandlund JT, Downing JR, Crist WM: Non-Hodgkin\u2019s lymphoma in childhood. N Engl J Med 1996, 334:1238\u20131248.","journal-title":"N Engl J Med"},{"key":"58_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02988618","volume":"16","author":"M Sasaki","year":"2002","unstructured":"Sasaki M, Kuwabara Y, Koga H, et al.: Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002, 16:337\u2013345.","journal-title":"Ann Nucl Med"},{"key":"58_CR11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-002-0861-y","volume":"29","author":"F Montravers","year":"2002","unstructured":"Montravers F, McNamara D, Landman-Parker J, et al.: [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002, 29:1155\u20131165.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"58_CR12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","volume":"94","author":"G Jerusalem","year":"1999","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94:429\u2013433.","journal-title":"Blood"},{"key":"58_CR13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","volume":"19","author":"K Spaepen","year":"2001","unstructured":"Spaepen K, Stroobants S, Dupont P, et al.: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin\u2019s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001, 19:414\u2013419.","journal-title":"J Clin Oncol"},{"key":"58_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-004-1604-z","volume":"32","author":"G Depas","year":"2005","unstructured":"Depas G, De Barsy C, Jerusalem G, et al.: 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005, 32:31\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"58_CR15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.mibio.2004.08.004","volume":"6","author":"M Allen-Auerbach","year":"2004","unstructured":"Allen-Auerbach M, Quon A, Weber WA, et al.: Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography\/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004, 6:411\u2013416.","journal-title":"Mol Imaging Biol"},{"key":"58_CR16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0022-3468(92)90318-2","volume":"27","author":"MP LaQuaglia","year":"1992","unstructured":"LaQuaglia MP, Stolar CJ, Krailo M, et al.: The role of surgery in abdominal non-Hodgkin\u2019s lymphoma: experience from the Children\u2019s Cancer Study Group. J Pediatr Surg 1992, 27:230\u2013235.","journal-title":"J Pediatr Surg"},{"key":"58_CR17","unstructured":"Cairo MS, Gerrard M, Sposto R, et al.: Results of a randomized FAB LMB96 international study in children and adolescents (C + A) with advanced B-NHL: Pts with L3 leukemia\/CNS- have an excellent prognosis. American Society of Clinical Oncology 39th Annual Meeting. Chicago, IL: May 31\u2013June 3, 2003."},{"key":"58_CR18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mpo.2950010307","volume":"1","author":"N Wollner","year":"1975","unstructured":"Wollner N, Burchenal JH, Lieberman PH, et al.: Non-Hodgkin\u2019s lymphoma in children. Med Pediatr Oncol 1975, 1:235\u2013263.","journal-title":"Med Pediatr Oncol"},{"key":"58_CR19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2003.04134.x","volume":"120","author":"MS Cairo","year":"2003","unstructured":"Cairo MS, Sposto R, Perkins SL, et al.: Burkitt\u2019s and Burkitt-like lymphoma in children and adolescents: a review of the Children\u2019s Cancer Group experience. Br J Haematol 2003, 120:660\u2013670.","journal-title":"Br J Haematol"},{"key":"58_CR20","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","volume":"97","author":"C Patte","year":"2001","unstructured":"Patte C, Auperin A, Michon J, et al: The Societe Francaise d\u2019Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370\u20133379.","journal-title":"Blood"},{"key":"58_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mpo.2950200204","volume":"20","author":"C Patte","year":"1992","unstructured":"Patte C, Kalifa C, Flamant F, et al.: Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992, 20:105\u2013113.","journal-title":"Med Pediatr Oncol"},{"key":"58_CR22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.1989.7.1.92","volume":"7","author":"AT Meadows","year":"1989","unstructured":"Meadows AT, Sposto R, Jenkin RD, et al.: Similar efficacy of 6 and 18\u00a0months of therapy with four drugs (COMP) for localized non-Hodgkin\u2019s lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 1989, 7:92\u201399.","journal-title":"J Clin Oncol"},{"key":"58_CR23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/cncr.11615","volume":"98","author":"J Mora","year":"2003","unstructured":"Mora J, Filippa DA, Qin J, Wollner N: Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial Sloan-Kettering Cancer Center. Cancer 2003, 98:1283\u20131291.","journal-title":"Cancer"},{"key":"58_CR24","first-page":"416","volume":"95","author":"A Reiter","year":"2000","unstructured":"Reiter A, Schrappe M, Ludwig WD, et al.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000, 95:416\u2013421.","journal-title":"Blood"},{"key":"58_CR25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1096-911X(200007)35:1<20::AID-MPO4>3.0.CO;2-L","volume":"35","author":"O Neth","year":"2000","unstructured":"Neth O, Seidemann K, Jansen P, et al.: Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 2000, 35:20\u201327.","journal-title":"Med Pediatr Oncol"},{"key":"58_CR26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199710303371802","volume":"337","author":"MP Link","year":"1997","unstructured":"Link MP, Shuster JJ, Donaldson SS, et al.: Treatment of children and young adults with early-stage non-Hodgkin\u2019s lymphoma. N Engl J Med 1997, 337:1259\u20131266.","journal-title":"N Engl J Med"},{"key":"58_CR27","first-page":"3294","volume":"94","author":"A Reiter","year":"1999","unstructured":"Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999, 94:3294\u20133306.","journal-title":"Blood"},{"key":"58_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ajh.10262","volume":"72","author":"MS Cairo","year":"2003","unstructured":"Cairo MS, Sposto R, Hoover-Regan M, et al.: Childhood and adolescent large-cell lymphoma (LCL): a review of the Children\u2019s Cancer Group experience. Am J Hematol 2003, 72:53\u201363.","journal-title":"Am J Hematol"},{"key":"58_CR29","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","volume":"97","author":"K Seidemann","year":"2001","unstructured":"Seidemann K, Tiemann M, Schrappe M, et al.: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001, 97:3699\u20133706.","journal-title":"Blood"},{"key":"58_CR30","first-page":"3591","volume":"92","author":"L Brugieres","year":"1998","unstructured":"Brugieres L, Deley MC, Pacquement H, et al.: CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998, 92:3591\u20133598.","journal-title":"Blood"},{"key":"58_CR31","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/cncr.21438","volume":"104","author":"A Rosolen","year":"2005","unstructured":"Rosolen A, Pillon M, Garaventa A, et al.: Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 2005, 104:2133\u20132140.","journal-title":"Cancer"},{"key":"58_CR32","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"58_CR33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00043426-199807000-00002","volume":"20","author":"RE Goldsby","year":"1998","unstructured":"Goldsby RE, Carroll WL: The molecular biology of pediatric lymphomas. J Pediatr Hematol Oncol 1998, 20:282\u2013296.","journal-title":"J Pediatr Hematol Oncol"},{"key":"58_CR34","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.ejca.2005.08.017","volume":"41","author":"R Ponzielli","year":"2005","unstructured":"Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ: Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005, 41:2485\u20132501.","journal-title":"Eur J Cancer"},{"key":"58_CR35","first-page":"383","volume":"60","author":"C Cinti","year":"2000","unstructured":"Cinti C, Claudio PP, Howard CM: Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2\/p130 in human tumor cell lines and primary tumors. Cancer Res 2000, 60:383\u2013389.","journal-title":"Cancer Res"},{"key":"58_CR36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/jcp.56.3.188","volume":"56","author":"C Bellan","year":"2003","unstructured":"Bellan C, Lazzi S, De Falco G: Burkitt\u2019s lymphoma: new insights into molecular pathogenesis. J Clin Pathol 2003, 56:188\u2013192.","journal-title":"J Clin Pathol"},{"key":"58_CR37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pbc.20342","volume":"45","author":"MS Cairo","year":"2005","unstructured":"Cairo MS, Raetz E, Lim MS, et al.: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer 2005, 45:753\u2013769.","journal-title":"Pediatr Blood Cancer"},{"key":"58_CR38","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL, et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871\u20133879.","journal-title":"Blood"},{"key":"58_CR39","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1200\/JCO.2000.18.22.3845","volume":"18","author":"MA Lones","year":"2000","unstructured":"Lones MA, Perkins SL, Sposto R, et al.: Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children\u2019s Cancer Group report. J Clin Oncol 2000, 18:3845\u20133853.","journal-title":"J Clin Oncol"},{"key":"58_CR40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1309\/TLE8FN6EYF0NJGP7","volume":"121","author":"X Liang","year":"2004","unstructured":"Liang X, Meech SJ, Odom LF, et al.: Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK + anaplastic large cell lymphoma. Am J Clin Pathol 2004, 121:496\u2013506.","journal-title":"Am J Clin Pathol"},{"key":"58_CR41","first-page":"59","volume":"30","author":"M Ladanyi","year":"1997","unstructured":"Ladanyi M: The NPM\/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv 1997, 30:59\u201375.","journal-title":"Cancer Surv"},{"key":"58_CR42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0301-472X(03)00007-9","volume":"31","author":"H Ruchatz","year":"2003","unstructured":"Ruchatz H, Coluccia AM, Stano P, et al.: Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM\/ALK-transformed cells. Exp Hematol 2003, 31:309\u2013315.","journal-title":"Exp Hematol"},{"key":"58_CR43","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood.V96.13.4319","volume":"96","author":"RY Bai","year":"2000","unstructured":"Bai RY, Ouyang T, Miething C, et al.: Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase\/Akt antiapoptotic signaling pathway. Blood 2000, 96:4319\u20134327.","journal-title":"Blood"},{"key":"58_CR44","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/10428190500126547","volume":"46","author":"A Muto","year":"2005","unstructured":"Muto A, Nakagawa A, Shimomura Y, Kitagawa Y, Tsurusawa M: Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro. Leuk Lymphoma 2005, 46:1489\u20131496.","journal-title":"Leuk Lymphoma"},{"key":"58_CR45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","volume":"11","author":"L Brugieres","year":"2000","unstructured":"Brugieres L, Quartier P, Le Deley MC, et al.: Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children\u2014a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53\u201358.","journal-title":"Ann Oncol"},{"key":"58_CR46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10024-004-8087-6","volume":"8","author":"S Kumar","year":"2005","unstructured":"Kumar S, Pittaluga S, Raffeld M, et al.: Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 2005, 8:52\u201360.","journal-title":"Pediatr Dev Pathol"},{"key":"58_CR47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235\u2013242.","journal-title":"N Engl J Med"},{"key":"58_CR48","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2004.04925.x","volume":"125","author":"MJ Vries de","year":"2004","unstructured":"de Vries MJ, Veerman AJ, Zwaan CM: Rituximab in three children with relapsed\/refractory B-cell acute lymphoblastic leukaemia\/Burkitt non-Hodgkin\u2019s lymphoma. Br J Haematol 2004, 125:414\u2013415.","journal-title":"Br J Haematol"},{"key":"58_CR49","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Raetz EA, Borowitz, MJ, Devidas M, et al.: Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study [corrected]. J Clin Oncol 2008, 26(24):3971\u20133978. This paper serves as the backbone for all new Children\u2019s Oncology Group protocols on which new agents are being introduced in contemporary studies. It established the \u201ctriple block\u201d therapy as a standard of care of pediatric patients with relapsed ALL in the United States.","DOI":"10.1200\/JCO.2008.16.1414"},{"issue":"12","key":"58_CR50","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/MPH.0b013e3181bdf211","volume":"31","author":"L Herrera","year":"2009","unstructured":"Herrera L, Bostrom B, Gore L, et al.: A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009, 31(12):936\u2013941.","journal-title":"J Pediatr Hematol Oncol"},{"key":"58_CR51","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mullighan CG, Zhang J, Harvey RC, et al.: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106(23):9414\u20139418. This paper is the first comprehensive analysis of JAK mutations in pediatric ALL.","DOI":"10.1073\/pnas.0811761106"},{"issue":"2","key":"58_CR52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","volume":"22","author":"J Adams","year":"2004","unstructured":"Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004, 22(2):304\u2013311.","journal-title":"Cancer Invest"},{"issue":"9","key":"58_CR53","first-page":"3535","volume":"61","author":"JC Cusack Jr","year":"2001","unstructured":"Cusack JC Jr, Liu R, Houston M, et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001, 61(9):3535\u20133540.","journal-title":"Cancer Res"},{"issue":"10","key":"58_CR54","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","volume":"10","author":"J Cortes","year":"2004","unstructured":"Cortes J, Thomas D, Koller C, et al.: Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004, 10(10):3371\u20133376.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"58_CR55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","volume":"50","author":"PJ Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Kolb EA, et al.: Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50(1):37\u201345.","journal-title":"Pediatr Blood Cancer"},{"key":"58_CR56","doi-asserted-by":"crossref","unstructured":"\u2022 Robak T, Lech-Maranda E, Korycka A, Robak E: Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006, 13(26):3165\u20133189. This paper provides a nice overview of nucleoside analogues in current use.","DOI":"10.2174\/092986706778742918"},{"issue":"18","key":"58_CR57","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","volume":"12","author":"MH Cohen","year":"2006","unstructured":"Cohen MH, Johnson JR, Massie T, et al.: Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Clin Cancer Res 2006, 12(18):5329\u20135335.","journal-title":"Clin Cancer Res"},{"key":"58_CR58","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(37):5541\u20135552. This paper provides an excellent overview of histone modification, acetylation, and transcriptional gene activation.","DOI":"10.1038\/sj.onc.1210620"},{"issue":"2","key":"58_CR59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104(2):155\u2013162.","journal-title":"J Clin Invest"},{"issue":"8","key":"58_CR60","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","volume":"92","author":"L Pukac","year":"2005","unstructured":"Pukac L, Kanakaraj P, Humphreys R, et al.: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005, 92(8):1430\u20131441.","journal-title":"Br J Cancer"},{"issue":"2","key":"58_CR61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/pbc.22188","volume":"54","author":"MA Smith","year":"2010","unstructured":"Smith MA, Morton CL, Kolb EA, et al.: Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010, 54(2):307\u2013310.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-010-0058-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0058-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T23:55:19Z","timestamp":1740268519000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-010-0058-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,17]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s11899-010-0058-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2010,7,17]]}}}